Meyahealth
HomeGeneticsGeneNFKBIA gene
Back to Gene
NFKBIA gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

NFKBIA gene

The NFKBIA gene provides instructions for making a protein that regulates nuclear factor-kappa-B, a complex essential for immune response and tissue development.

Normal Function

The NFKBIA gene provides instructions for making one piece (the alpha subunit) of the IKK protein complex, which regulates the activity of nuclear factor-kappa-B. Nuclear factor-kappa-B is a protein complex that binds to DNA and controls the activity of other genes. When inactive, nuclear factor-kappa-B is attached to the IKK complex.

The NFKBIA protein helps keep nuclear factor-kappa-B bound in the IKK complex. When the NFKBIA protein receives a signal that nuclear factor-kappa-B is to be released, it breaks down. Once released, the active factor moves into the nucleus and binds to DNA. Nuclear factor-kappa-B regulates genes that control immune responses, inflammatory reactions, and the formation of ectodermal tissues (skin, hair, teeth, and sweat glands). It also protects the cell from signals that would otherwise cause it to self-destruct (apoptosis).

Health Conditions Related to Genetic Changes

Anhidrotic ectodermal dysplasia with immune deficiency

At least five mutations in the NFKBIA gene have been found to cause anhidrotic ectodermal dysplasia with immune deficiency (EDA-ID). This condition is characterized by reduced immune system function, resulting in recurrent infections and abnormal development of ectodermal tissues. The NFKBIA gene mutations that cause EDA-ID impair the protein's breakdown. As a result, nuclear factor-kappa-B is not activated or released from the IKK complex, disrupting signaling pathways within immune cells and ectodermal tissues.

Other Names for This Gene

  • I-kappa-B-alpha
  • IkappaBalpha
  • ikB-alpha
  • IKBA
  • IKBA_HUMAN
  • MAD-3
  • major histocompatibility complex enhancer-binding protein MAD3
  • NF-kappa-B inhibitor alpha
  • NFKBI
  • nuclear factor of kappa light chain gene enhancer in B-cells
  • nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha

Genomic Location

The NFKBIA gene is found on chromosome 14.

Frequently Asked Questions

Individuals with EDA-ID have a compromised immune system, making them highly susceptible to recurrent and severe infections. Common infections include bacterial infections (such as pneumonia, otitis media, and skin infections), viral infections, and fungal infections. Precautions often involve strict hygiene, avoiding crowded environments, and prompt medical attention for any signs of infection. Treatment typically includes aggressive antibiotic therapy for bacterial infections, antiviral medications, and sometimes prophylactic antibiotics or immunoglobulin replacement therapy to boost immune function.
Currently, treatment for EDA-ID primarily focuses on managing symptoms and preventing infections. However, research is ongoing into targeted therapies that could address the underlying genetic defect. Since the NFKBIA gene's mutations prevent the proper activation of nuclear factor-kappa-B, researchers are exploring ways to restore this signaling pathway. Gene therapy approaches are also being investigated as potential long-term solutions to correct the genetic defect and improve immune and ectodermal development.
nhidrotic ectodermal dysplasia with immune deficiency (EDA-ID) specifically affects the development of ectodermal tissues. Common symptoms include sparse hair (hypotrichosis), missing or abnormally shaped teeth (hypodontia or anodontia), and reduced or absent sweating (anhidrosis). The lack of sweating can significantly impact daily life, leading to heat intolerance and a risk of overheating, especially during physical activity or in warm environments. Dental abnormalities can cause difficulties with eating and speech, while sparse hair can affect appearance and scalp protection.
EDA-ID is diagnosed based on a combination of clinical symptoms (ectodermal abnormalities and recurrent infections) and genetic testing to identify mutations in the NFKBIA gene. Blood tests may also show abnormalities in immune cell function. The condition is inherited in an X-linked recessive pattern. This means that males are typically more severely affected because they have only one X chromosome. Females can be carriers and may have milder symptoms or be asymptomatic. If a mother is a carrier, there is a 50% chance her sons will be affected and a 50% chance her daughters will be carriers.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ